Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy

British Journal of Dermatology

Volumn 140, Issue 6, 1999, Pages 1065-1071

  Hauschild, A ^a   Engel, G ^a   Brenner, W ^a   Glaser R ^a   Monig H ^a   Henze, E ^a   Christophers, E ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Chemotherapy; Metastatic malignant melanoma; Predictive value; Serum S100B

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; PROTEIN S 100; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; PREDICTIVE VALUE OF TESTS; S100 PROTEINS; SKIN NEOPLASMS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 0033023956     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02905.x     Document Type: Article

References (26)

1. 1 Roses DF, Karp NS, Oratz R, Dubin N. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 1991; 172: 252-8.
2. 2 Provost N, Marghoob AA, Kopf AW et al. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma: a survey of experienced physicians. J Am Acad Dermatol 1997; 36: 711-20.
3. 3 Leyvraz S, Spataro V, Bauer J et al. Treatment of ocular melanoma metastasis to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15: 2589-95.
4. 4 Keilholz V, Goey SH, Punl CJA et al. Interferon-alpha-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative-Group. J Clin Oncol 1997; 15: 2579-88.
5. 5 Wimmer I, Meyer JC, Seifert B et al. Prognostic value of serum 5-S-Cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 1997; 57: 5073-6.
6. 6 Nakajima T, Watanabe S, Sato Y et al. An immunoperoxidase study of S 100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 1982; 7: 715-27.
7. 7 Takahashi K, Isobe T, Ohtsuki Y et al. Immunohistochemical localization and distribution of S100 proteins in the human lymphoreticular system. Am J Pathol 1984; 116: 497-503.
8. 8 Gatter KC, Ralfkiaer E, Skinner J et al. An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 1985; 38: 1353-7.
9. 9 Cho KH, Hashimoto K, Taniguchi Y et al. Immunohistochemical study of melanocytic naevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 1990; 66: 765-71.
10. 10 Persson L, Härdemark HG, Gustavsson J et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987; 18: 911-18.
11. 11 Fagnart OC, Sindic CJ, Laterre C. Particle counting immunoassay of S 100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 1988; 34: 1387-91.
12. 12 Aurell A, Rosengarten LE, Wikkelsö C et al. The S-100 protein in cerebrospinal fluid: a simple ELISA method. J Neurol Sci 1989; 89: 157-64.
13. 13 Guo H, Stoffel-Wagner B, Bierwierth T et al. Clinical significance of serum S 100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A: 924-8.
14. 14 von Schoultz E, Hansson LO, Djureen E et al. Prognostic value of serum analyses of S100β protein in malignant melanoma. Melanoma Res 1996; 6: 133-7.
15. 15 Henze G, Dummer R, Joller-Jemelka H1 et al. Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology 1997; 194: 208-12.
16. 16 Buer J, Probst M, Franzke A et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997; 75: 1373-6.
17. 17 Abraha HD, Fuller LC, Du Vivier AWP et al. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997; 137: 381-5.
18. 18 Schultz ES, Diepgen TL, von den Driesch P. Clinical and prognostic relevance of serum S100B protein in malignant melanoma. Br J Dermatol 1997; 138: 426-30.
19. 19 American Joint Committee on Cancer. Manual for Staging of Cancer, 3rd edn. Philadelphia: JB Lippincott, 1988: 143-8.
20. 20 Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-9.
21. 21 Brossart P, Keilholz U, Willhauck M et al. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993; 101: 887-9.
22. 22 Foss AJE, Guille MJ, Oceleston et al. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995; 72: 155-9.
23. 23 Reinhold U, Lüdtke-Hadjery H-C, Schnautz S et al. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997; 108: 166-9.
24. 24 Gläser R, Rass K, Seiter S et al. Detection of circulating melanoma cells by spocific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 1997; 15: 2818-25.
25. 25 Jung FA, Buzaid AC, Ross MI et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997; 15: 2226-31.
26. 26 Bosserhoff AK, Kaufman M, Kaluza B et al. Melanoma inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149-53.